Video
Dr. Saad on Next Steps for Radium-223 in mCRPC
Author(s):
Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.
Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Next steps with this therapy include examining this agent in combination with other drugs, such as abiraterone and enzalutamide, Saad explains. A phase II study also examined the safety of radium-223 when added to chemotherapy, which showed promise.
There are no safety concerns with administering radium-223 before or after chemotherapy, he adds.
